CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP)
US23254L2079
We assign a fundamental rating of 2 out of 10 to CYCCP. CYCCP was compared to 561 industry peers in the Biotechnology industry. Both the profitability and financial health of CYCCP have multiple concerns. While showing a medium growth rate, CYCCP is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CYCCP has reported negative net income.
CYCCP had a negative operating cash flow in the past year.
In the past 5 years CYCCP always reported negative net income.
CYCCP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -250.53%, CYCCP is not doing good in the industry: 92.79% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -250.53% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CYCCP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CYCCP does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYCCP has less shares outstanding than it did 1 year ago.
CYCCP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CYCCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CYCCP has an Altman-Z score of -118.70. This is a bad value and indicates that CYCCP is not financially healthy and even has some risk of bankruptcy.
CYCCP has a Altman-Z score of -118.70. This is amonst the worse of the industry: CYCCP underperforms 98.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -118.7 |
ROIC/WACCN/A
WACC10.68%
2.3 Liquidity
CYCCP has a Current Ratio of 0.77. This is a bad value and indicates that CYCCP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.77, CYCCP is not doing good in the industry: 90.63% of the companies in the same industry are doing better.
CYCCP has a Quick Ratio of 0.77. This is a bad value and indicates that CYCCP is not financially healthy enough and could expect problems in meeting its short term obligations.
CYCCP's Quick ratio of 0.77 is on the low side compared to the rest of the industry. CYCCP is outperformed by 90.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.77 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
CYCCP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.67%, which is quite impressive.
The Revenue for CYCCP has decreased by -80.83% in the past year. This is quite bad
Measured over the past years, CYCCP shows a very strong growth in Revenue. The Revenue has been growing by 22.87% on average per year.
EPS 1Y (TTM)68.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
Revenue 1Y (TTM)-80.83%
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Sales Q2Q%-37.5%
3.2 Future
The Earnings Per Share is expected to grow by 17.14% on average over the next years. This is quite good.
Based on estimates for the next years, CYCCP will show a very strong growth in Revenue. The Revenue will grow by 213.65% on average per year.
EPS Next Y92.7%
EPS Next 2Y39.85%
EPS Next 3Y25.1%
EPS Next 5Y17.14%
Revenue Next Year-86.38%
Revenue Next 2Y-49.3%
Revenue Next 3Y-36.42%
Revenue Next 5Y213.65%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CYCCP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CYCCP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CYCCP's earnings are expected to grow with 25.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.85%
EPS Next 3Y25.1%
5. Dividend
5.1 Amount
CYCCP has a Yearly Dividend Yield of 1.79%. Purely for dividend investing, there may be better candidates out there.
CYCCP's Dividend Yield is rather good when compared to the industry average which is at 8.98. CYCCP pays more dividend than 98.74% of the companies in the same industry.
Compared to the average S&P500 Dividend Yield of 2.33, CYCCP is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.79% |
5.2 History
The dividend of CYCCP decreases each year by -38.18%.
CYCCP has been paying a dividend for over 5 years, so it has already some track record.
CYCCP has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-38.18%
Div Incr Years0
Div Non Decr Years2
5.3 Sustainability
The earnings of CYCCP are negative and hence is the payout ratio. CYCCP will probably not be able to sustain this dividend level.
DP-0.37%
EPS Next 2Y39.85%
EPS Next 3Y25.1%
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (1/10/2025, 8:12:00 PM)
7.6
-0.28 (-3.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners18.63%
Inst Owner Change0%
Ins Owners2.48%
Ins Owner ChangeN/A
Market Cap47.80M
Analysts43.33
Price Target18.95 (149.34%)
Short Float %0%
Short Ratio0
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.79% |
Dividend Growth(5Y)-38.18%
DP-0.37%
Div Incr Years0
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.51%
Min EPS beat(2)50.81%
Max EPS beat(2)68.2%
EPS beat(4)3
Avg EPS beat(4)42.12%
Min EPS beat(4)-3.64%
Max EPS beat(4)68.2%
EPS beat(8)5
Avg EPS beat(8)19.9%
EPS beat(12)9
Avg EPS beat(12)22.73%
EPS beat(16)10
Avg EPS beat(16)7.81%
Revenue beat(2)1
Avg Revenue beat(2)4.58%
Min Revenue beat(2)-86.93%
Max Revenue beat(2)96.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-78.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)88.8%
EPS NY rev (1m)37.7%
EPS NY rev (3m)37.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)23.26%
Revenue NY rev (3m)23.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 646 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-9.4
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0.01
BVpS-0.15
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -250.53% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.77 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | -118.7 |
F-Score2
WACC10.68%
ROIC/WACCN/A
Cap/Depr(3y)42.56%
Cap/Depr(5y)135.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
EPS Next Y92.7%
EPS Next 2Y39.85%
EPS Next 3Y25.1%
EPS Next 5Y17.14%
Revenue 1Y (TTM)-80.83%
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Sales Q2Q%-37.5%
Revenue Next Year-86.38%
Revenue Next 2Y-49.3%
Revenue Next 3Y-36.42%
Revenue Next 5Y213.65%
EBIT growth 1Y46.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.83%
OCF growth 3YN/A
OCF growth 5YN/A